Superluminal Medicines, Inc. — Form D
Superluminal Medicines, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2024-09-04. The offering totals $120.0M, of which $20.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-09-04
- Form: D
- Accession: 0001989478-24-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $120.0M
- Amount sold: $20.0M
- Remaining: $100.0M
- Investors: 12
- Date of first sale: 2024-08-21
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-523131
Issuer
- Name: Superluminal Medicines, Inc.
- CIK: 0001989478
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2023
- Address: 15 NECCO ST., BOSTON, MA, 02110
- Phone: (301) 525-8752
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| CATHERINE RIESEN | Executive Officer | WALTHAM, MA |
| Andrew Levin | Director | BOSTON, MA |
| DYLAN MORRIS | Director | Watertown, MA |
| DIAMANTIS XYLAS | Director | SOUTH SAN FRANCISCO, CA |
| CONY D'CRUZ | Director | BOSTON, MA |
| CONY D'CRUZ | Executive Officer | BOSTON, MA |
| CONY D'CRUZ | Promoter | BOSTON, MA |
| CRAIG RANDALL | Executive Officer | BOSTON, MA |
Other filings by this issuer (2)
More